Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost

Woo Joo Kim; Christine C. Roberts; Joon Young Song; Jin Gu Yoon; Hye Seong; Hak Jun Hyun; Hyojin Lee; Areum Gil; Yeeun Oh; Ji Eun Park; Ji Eun Lee; Bohyun Jeon; Deborah Kane; Susan Spruill; Sagar B. Kudchodkar; Kar Muthumani; Young K. Park; Ijoo Kwon; Joel N. Maslow

doi:10.1016/j.vaccine.2023.06.013

Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost

Woo Joo Kim, Christine C. Roberts, Joon Young Song, Jin Gu Yoon, Hye Seong, Hak Jun Hyun, Hyojin Lee, Areum Gil, Yeeun Oh, Ji Eun Park, Ji Eun Lee, Bohyun Jeon, Deborah Kane, Susan Spruill, Sagar B. Kudchodkar, Kar Muthumani, Young K. Park, Ijoo Kwon, Joel N. Maslow

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.

Original language	English (US)
Pages (from-to)	4206-4211
Number of pages	6
Journal	Vaccine
Volume	41
Issue number	29
DOIs	https://doi.org/10.1016/j.vaccine.2023.06.013
State	Published - Jun 29 2023

Keywords

Humans
Antibodies, Neutralizing
Antibodies, Viral
COVID-19/prevention & control
COVID-19 Vaccines
DNA
SARS-CoV-2
Vaccination
Vaccines, DNA

ASJC Scopus subject areas

veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases
Molecular Medicine
Immunology and Microbiology(all)

Access to Document

10.1016/j.vaccine.2023.06.013

Cite this

Kim, W. J., Roberts, C. C., Song, J. Y., Yoon, J. G., Seong, H., Hyun, H. J., Lee, H., Gil, A., Oh, Y., Park, J. E., Lee, J. E., Jeon, B., Kane, D., Spruill, S., Kudchodkar, S. B., Muthumani, K., Park, Y. K., Kwon, I., & Maslow, J. N. (2023). Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost. Vaccine, 41(29), 4206-4211. https://doi.org/10.1016/j.vaccine.2023.06.013

Kim, WJ, Roberts, CC, Song, JY, Yoon, JG, Seong, H, Hyun, HJ, Lee, H, Gil, A, Oh, Y, Park, JE, Lee, JE, Jeon, B, Kane, D, Spruill, S, Kudchodkar, SB, Muthumani, K, Park, YK, Kwon, I & Maslow, JN 2023, 'Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost', Vaccine, vol. 41, no. 29, pp. 4206-4211. https://doi.org/10.1016/j.vaccine.2023.06.013

@article{e4a46f5b6e74423f96b3312727fe7350,

title = "Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost",

abstract = "Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.",

keywords = "Humans, Antibodies, Neutralizing, Antibodies, Viral, COVID-19/prevention & control, COVID-19 Vaccines, DNA, SARS-CoV-2, Vaccination, Vaccines, DNA",

author = "Kim, {Woo Joo} and Roberts, {Christine C.} and Song, {Joon Young} and Yoon, {Jin Gu} and Hye Seong and Hyun, {Hak Jun} and Hyojin Lee and Areum Gil and Yeeun Oh and Park, {Ji Eun} and Lee, {Ji Eun} and Bohyun Jeon and Deborah Kane and Susan Spruill and Kudchodkar, {Sagar B.} and Kar Muthumani and Park, {Young K.} and Ijoo Kwon and Maslow, {Joel N.}",

note = "Funding Information: Study support was provided by the Korea Health Technology R&D Project through Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare , Republic of Korea (grant HQ20C0040 ). Funding Information: Study support was provided by the Korea Health Technology R&D Project through Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare, Republic of Korea (grant HQ20C0040). Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = jun,

day = "29",

doi = "10.1016/j.vaccine.2023.06.013",

language = "English (US)",

volume = "41",

pages = "4206--4211",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "29",

}

TY - JOUR

T1 - Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost

AU - Kim, Woo Joo

AU - Roberts, Christine C.

AU - Song, Joon Young

AU - Yoon, Jin Gu

AU - Seong, Hye

AU - Hyun, Hak Jun

AU - Lee, Hyojin

AU - Gil, Areum

AU - Oh, Yeeun

AU - Park, Ji Eun

AU - Lee, Ji Eun

AU - Jeon, Bohyun

AU - Kane, Deborah

AU - Spruill, Susan

AU - Kudchodkar, Sagar B.

AU - Muthumani, Kar

AU - Park, Young K.

AU - Kwon, Ijoo

AU - Maslow, Joel N.

N1 - Funding Information: Study support was provided by the Korea Health Technology R&D Project through Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare , Republic of Korea (grant HQ20C0040 ). Funding Information: Study support was provided by the Korea Health Technology R&D Project through Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare, Republic of Korea (grant HQ20C0040). Publisher Copyright: © 2023 The Author(s)

PY - 2023/6/29

Y1 - 2023/6/29

N2 - Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.

AB - Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.

KW - Humans

KW - Antibodies, Neutralizing

KW - Antibodies, Viral

KW - COVID-19/prevention & control

KW - COVID-19 Vaccines

KW - DNA

KW - SARS-CoV-2

KW - Vaccination

KW - Vaccines, DNA

UR - http://www.scopus.com/inward/record.url?scp=85161719272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85161719272&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2023.06.013

DO - 10.1016/j.vaccine.2023.06.013

M3 - Article

C2 - 37296017

AN - SCOPUS:85161719272

SN - 0264-410X

VL - 41

SP - 4206

EP - 4211

JO - Vaccine

JF - Vaccine

IS - 29

ER -

Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this